O.S. Mikhaylova1, A.I. Murtazin5, I.S. Raginov1-4
1Kazan State Medical University, Kazan
2Volga Region branch of N.N. Blokhin Russian Cancer Research Center, Kazan
3Kazan (Volga Region) Federal University, Kazan
4Republican Clinical Hospital, Kazan
5Petrov Research Institute of Oncology, Saint Petersburg
Raginov Ivan S. — D. Sc. (medicine), Head of the Pathology Department of Republican Clinical Hospital, Professor of the Department of Biomedical Engineering and Innovation Management of the Engineering Institute of Kazan (Volga Region) Federal University, Associate Professor of the Departments of Histology and Pathology of Kazan State Medical University
138 Orenburgskiy Trakt, Kazan, Russian Federation, 420064, tel. +7-903-340-18-81, e-mail: email@example.com
Abstract. Mesenchymal hamartoma of the liver (MHL) is a rare benign liver neoplasm that occurs mainly in children. The etiology and pathogenesis of MHL are not yet well understood. This report describes the pathological and immunohistochemical profiles of liver hamartoma in an elderly patient, as well as provides a brief review of the literature about markers that can be detected during immunohistochemical staining of MHL sample in adult patients.
Material and methods. A morphological study of a 79-year-old patient’s liver sample was performed which was initially diagnosed with «cholangiocarcinoma».
Results. When using antibodies against alpha-fetoprotein and cytokeratin-7, immunohistochemical staining is visualized in the cytoplasm of hepatocytes and some cholangiocytes, and with CD-10 antibodies — on the cytoplasmic membrane of these cells; to TTF-1 — negatively.
Conclusions. Data from morphological and immunohistochemical studies indicate the presence of mesenchymal hamartoma of the liver in this patient. Alpha-fetoprotein and CD10 that are usually considered as hepatocellular cancer markers can rather be expressed in liver hamartoma cells.
Key words: mesenchymal hamartoma of the liver, AFP, CD7, immunohistochemistry.